<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01866098</url>
  </required_header>
  <id_info>
    <org_study_id>1207010507</org_study_id>
    <secondary_id>1R01DK093924-01A1</secondary_id>
    <nct_id>NCT01866098</nct_id>
  </id_info>
  <brief_title>Naltrexone for Antipsychotic-Induced Weight Gain</brief_title>
  <acronym>NTX</acronym>
  <official_title>Naltrexone for Antipsychotic-Induced Weight Gain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to look at the effects of naltrexone on weight loss in individuals
      treated with antipsychotic medications. Naltrexone is an FDA approved medication for the
      management of alcohol dependence and drug dependence, but has not been fully evaluated for
      its effect on weight loss in individuals with severe mental illness (i.e. schizophrenia,
      schizoaffective disorder, bipolar disorder etc.) The purpose of this study is to find out how
      effective two different doses of oral naltrexone is on reducing body weight when compared to
      placebo (an inactive substance or &quot;sugar pill&quot;).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Persons with severe mental illness (SMI) die, on average, 25 years earlier than the general
      population1. Most of this early mortality can be attributed to cardiovascular disease (CVD)
      and diabetes mellitus (DM), which are directly related to obesity. Obesity is a leading cause
      of preventable death in the United States, second only to smoking. The physical health of
      patients has become a major focus of schizophrenia care, as recent decades have seen immense
      gains in symptom control and community integration. There is an urgent need for the
      development of interventions that address the obesity crisis in schizophrenia.

      Patients treated with antipsychotic medications have been shown to have a preference for
      diets high in fat and sugar. Patients with schizophrenia typically seek behaviors that
      increase dopamine mediated reward in the brain such as smoking and substance use, both of
      which occur more often in this group than the general population. The system might require
      intact dopamine and opioid function.

      Naltrexone is an oral agent that competitively antagonizes all known opioid receptors in the
      brain. Human studies with naltrexone were completed in individuals with different illnesses,
      including schizophrenia, and have been shown to be a safe and easy agent to use. It is shown
      to decrease craving in alcoholics and is approved by the FDA for the treatment of alcohol
      dependence. Naltrexone is reported to decrease craving for other substances of abuse, like
      nicotine. Furthermore, it has been shown to prevent secondary weight gain due to cessation of
      cigarette smoking at low (25mg and 50 mg), but not higher doses. Naltrexone has been tested
      in human feeding studies, and has been shown to reduce both the quantity of food eaten and
      the choice of palatable foods.

      Subjects will be randomized to either 25, 50 or 0mg of Naltrexone and will take the study
      medication daily for 52 weeks. Subjects will be seen weekly for the first 4 weeks of the
      study, thereafter they will be seen on a bi-weekly (every other week) basis to be assessed
      (i.e. weight, side effect check, paper questionnaires) throughout the remaining 48 weeks of
      treatment.

      The purpose of this study is to determine the efficacy of two doses of naltrexone (25mg &amp;
      50mg) versus placebo for weight and health risk reduction in 144 obese individuals with
      severe mental illness treated with an antipsychotic medication.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">April 7, 2019</completion_date>
  <primary_completion_date type="Actual">April 7, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Weight From Baseline</measure>
    <time_frame>52 weeks</time_frame>
    <description>Weight (kilograms; kg) will be measured at each assessment and change in weight will be determined at study endpoint.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Subjects Who Lost More Than 5% of Body Weight From Baseline</measure>
    <time_frame>52 weeks</time_frame>
    <description>Body Mass Index will be calculated at each assessment and change over time will be assessed at endpoint.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Fasting Glucose From Baseline</measure>
    <time_frame>Week 52</time_frame>
    <description>Fasting glucose will be collected over the course of participation and changes will be evaluated at study endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Glycosylated Hemoglobin (HbA1c) From Baseline</measure>
    <time_frame>Week 52</time_frame>
    <description>Glycosylated hemoglobin (HbA1c) will be collected over the course of participation and changes will be evaluated at study endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Insulin From Baseline</measure>
    <time_frame>Week 52</time_frame>
    <description>Insulin will be collected over the course of participation and changes will be evaluated at study endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Total Cholesterol From Baseline</measure>
    <time_frame>Week 52</time_frame>
    <description>Total Cholesterol will be collected over the course of participation and changes will be evaluated at study endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in HDL From Baseline</measure>
    <time_frame>Week 52</time_frame>
    <description>High-density lipoprotein (HDL) will be collected over the course of participation and changes will be evaluated at study endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in LDL From Baseline</measure>
    <time_frame>Week 52</time_frame>
    <description>Low-density lipoprotein (HDL) will be collected over the course of participation and changes will be evaluated at study endpoint.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">144</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <condition>Schizophreniform Disorder</condition>
  <condition>Bipolar Disorder</condition>
  <condition>Severe Major Depression With Psychotic Features</condition>
  <arm_group>
    <arm_group_label>Naltrexone 50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Naltrexone 50mg capsule taken once daily for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral placebo capsule taken once daily for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naltrexone 25mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Naltrexone 25mg capsule taken once daily for 52 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone</intervention_name>
    <description>25 or 50mg (randomized) oral capsule taken once daily for 52 weeks to establish optimal dose for weight loss over the course of the study.</description>
    <arm_group_label>Naltrexone 25mg</arm_group_label>
    <arm_group_label>Naltrexone 50mg</arm_group_label>
    <other_name>Revia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 75

          -  Meet Diagnostic &amp; Statistical Manual - 4 (DSM-IV) criteria for schizophrenia,
             schizoaffective disorder, bipolar disorder, major depression, or another psychotic
             disorder based on Structured Clinical Interview for the DSM-IV (SCID) interview

          -  Body Mass Index (BMI) of 28 and over

          -  On a stable dose of antipsychotic medication; i.e. at least one month with no dose
             change, and three months from an antipsychotic switch

          -  Deemed to be symptomatically stable by the clinical staff in the last two months

          -  Over 7% total body weight increase on antipsychotics for subjects within first year of
             illness

        Exclusion Criteria:

          -  Meet criteria for current opiate abuse or dependence (confirmed by positive urine drug
             screen for opiates or, if suspected by study doctor via patient history and or
             suspicion of occult opiate use, a naloxone challenge will be performed.)

          -  Current history of dementia, mental retardation

          -  Not capable of giving informed consent for participation in the study

          -  Women who are pregnant or breast-feeding

          -  Physical conditions affecting body weight (e.g. Cushing's disease, polycystic ovary
             syndrome) Diabetes Mellitus (defined as prescribed an anti-diabetic medication for
             diabetes or a hemoglobin A1c level &gt; 7 confirmed by primary care physician at
             screening)

          -  Severe liver dysfunction, (serum aminotransferases greater than three times normal),
             acute infectious hepatitis, liver failure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cenk Tek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Connecticut Mental Health Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 12, 2013</study_first_submitted>
  <study_first_submitted_qc>May 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2013</study_first_posted>
  <results_first_submitted>March 30, 2020</results_first_submitted>
  <results_first_submitted_qc>March 30, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 8, 2020</results_first_posted>
  <last_update_submitted>March 30, 2020</last_update_submitted>
  <last_update_submitted_qc>March 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>antipsychotic</keyword>
  <keyword>severe mental illness</keyword>
  <keyword>weight loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Weight Gain</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All de-identified data resulting from this award involving human subjects will be submitted to the NIMH Data Archive (NDA) - National Database for Clinical Trials Related to Mental Illness (NDCT) The Principal Investigator will work with NDA support staff to plan an appropriate data submission schedule and provide information on the steps for submission and sharing of data. Communication of this data sharing plan to appropriate research staff to ensure the timely submission of data. All human subject data provided will include an NDA Global Unique Identifier (GUID) and will not include personally identifiable information (PII). Analyzed data will be submitted no later than the time of publication. Even if a publication focuses on only part of an analyzed dataset, the entire analyzed dataset will be submitted when the first paper is published. All data made available for public use via NDA will be de-identified data.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 16, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/98/NCT01866098/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Oral placebo capsule taken once daily for 52 weeks
Placebo</description>
        </group>
        <group group_id="P2">
          <title>Naltrexone 25mg</title>
          <description>Oral Naltrexone 25mg capsule taken once daily for 52 weeks
Naltrexone: 25 or 50mg (randomized) oral capsule taken once daily for 52 weeks to establish optimal dose for weight loss over the course of the study.</description>
        </group>
        <group group_id="P3">
          <title>Naltrexone 50mg</title>
          <description>Oral Naltrexone 50mg capsule taken once daily for 52 weeks
Naltrexone: 25 or 50mg (randomized) oral capsule taken once daily for 52 weeks to establish optimal dose for weight loss over the course of the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unrelated Hospitalization</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Oral placebo capsule taken once daily for 52 weeks
Placebo</description>
        </group>
        <group group_id="B2">
          <title>Naltrexone 25mg</title>
          <description>Oral Naltrexone 25mg capsule taken once daily for 52 weeks
Naltrexone: 25 or 50mg (randomized) oral capsule taken once daily for 52 weeks to establish optimal dose for weight loss over the course of the study.</description>
        </group>
        <group group_id="B3">
          <title>Naltrexone 50mg</title>
          <description>Oral Naltrexone 50mg capsule taken once daily for 52 weeks
Naltrexone: 25 or 50mg (randomized) oral capsule taken once daily for 52 weeks to establish optimal dose for weight loss over the course of the study.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="51"/>
            <count group_id="B2" value="47"/>
            <count group_id="B3" value="46"/>
            <count group_id="B4" value="144"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.8" spread="12.8"/>
                    <measurement group_id="B2" value="45.0" spread="11.5"/>
                    <measurement group_id="B3" value="43.0" spread="14.2"/>
                    <measurement group_id="B4" value="43.6" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White/Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>BMI = weight in kg/ height m^2</description>
          <units>weight in kg/ height m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.1" spread="7.3"/>
                    <measurement group_id="B2" value="37.1" spread="5.7"/>
                    <measurement group_id="B3" value="38.9" spread="11.4"/>
                    <measurement group_id="B4" value="38.4" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Weight From Baseline</title>
        <description>Weight (kilograms; kg) will be measured at each assessment and change in weight will be determined at study endpoint.</description>
        <time_frame>52 weeks</time_frame>
        <population>Analysis population consists of participants who were randomized, received at least 1 dose of the trial compound (naltrexone or placebo), and had at least 1 assessment after baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral placebo capsule taken once daily for 52 weeks
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone 25mg</title>
            <description>Oral Naltrexone 25mg capsule taken once daily for 52 weeks
Naltrexone: 25 or 50mg (randomized) oral capsule taken once daily for 52 weeks to establish optimal dose for weight loss over the course of the study.</description>
          </group>
          <group group_id="O3">
            <title>Naltrexone 50mg</title>
            <description>Oral Naltrexone 50mg capsule taken once daily for 52 weeks
Naltrexone: 25 or 50mg (randomized) oral capsule taken once daily for 52 weeks to establish optimal dose for weight loss over the course of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Weight From Baseline</title>
          <description>Weight (kilograms; kg) will be measured at each assessment and change in weight will be determined at study endpoint.</description>
          <population>Analysis population consists of participants who were randomized, received at least 1 dose of the trial compound (naltrexone or placebo), and had at least 1 assessment after baseline.</population>
          <units>kg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.16" spread="1.78"/>
                    <measurement group_id="O2" value="0.69" spread="2.22"/>
                    <measurement group_id="O3" value="-0.95" spread="2.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.83</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Estimated treatment differences between groups analyzed using mixed-model analysis. Model includes the baseline value age; sex; compliance; ethnicity.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Subjects Who Lost More Than 5% of Body Weight From Baseline</title>
        <description>Body Mass Index will be calculated at each assessment and change over time will be assessed at endpoint.</description>
        <time_frame>52 weeks</time_frame>
        <population>Analysis population consists of participants who were randomized, received at least 1 dose of the trial compound (naltrexone or placebo), and had at least 1 assessment after baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral placebo capsule taken once daily for 52 weeks
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone 25mg</title>
            <description>Oral Naltrexone 25mg capsule taken once daily for 52 weeks
Naltrexone: 25 or 50mg (randomized) oral capsule taken once daily for 52 weeks to establish optimal dose for weight loss over the course of the study.</description>
          </group>
          <group group_id="O3">
            <title>Naltrexone 50mg</title>
            <description>Oral Naltrexone 50mg capsule taken once daily for 52 weeks
Naltrexone: 25 or 50mg (randomized) oral capsule taken once daily for 52 weeks to establish optimal dose for weight loss over the course of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects Who Lost More Than 5% of Body Weight From Baseline</title>
          <description>Body Mass Index will be calculated at each assessment and change over time will be assessed at endpoint.</description>
          <population>Analysis population consists of participants who were randomized, received at least 1 dose of the trial compound (naltrexone or placebo), and had at least 1 assessment after baseline.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.10</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Fasting Glucose From Baseline</title>
        <description>Fasting glucose will be collected over the course of participation and changes will be evaluated at study endpoint.</description>
        <time_frame>Week 52</time_frame>
        <population>Analysis population consists of participants who were randomized, received at least 1 dose of the trial compound (naltrexone or placebo), and had at least 1 assessment after baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral placebo capsule taken once daily for 52 weeks
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone 25mg</title>
            <description>Oral Naltrexone 25mg capsule taken once daily for 52 weeks
Naltrexone: 25 or 50mg (randomized) oral capsule taken once daily for 52 weeks to establish optimal dose for weight loss over the course of the study.</description>
          </group>
          <group group_id="O3">
            <title>Naltrexone 50mg</title>
            <description>Oral Naltrexone 50mg capsule taken once daily for 52 weeks
Naltrexone: 25 or 50mg (randomized) oral capsule taken once daily for 52 weeks to establish optimal dose for weight loss over the course of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Fasting Glucose From Baseline</title>
          <description>Fasting glucose will be collected over the course of participation and changes will be evaluated at study endpoint.</description>
          <population>Analysis population consists of participants who were randomized, received at least 1 dose of the trial compound (naltrexone or placebo), and had at least 1 assessment after baseline.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" spread="2.6"/>
                    <measurement group_id="O2" value="4.6" spread="3.2"/>
                    <measurement group_id="O3" value="-0.4" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.19</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Estimated treatment differences between groups analyzed using mixed-model analysis. Model includes the baseline value age; sex; compliance; ethnicity.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Glycosylated Hemoglobin (HbA1c) From Baseline</title>
        <description>Glycosylated hemoglobin (HbA1c) will be collected over the course of participation and changes will be evaluated at study endpoint.</description>
        <time_frame>Week 52</time_frame>
        <population>Analysis population consists of participants who were randomized, received at least 1 dose of the trial compound (naltrexone or placebo), and had at least 1 assessment after baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral placebo capsule taken once daily for 52 weeks
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone 25mg</title>
            <description>Oral Naltrexone 25mg capsule taken once daily for 52 weeks
Naltrexone: 25 or 50mg (randomized) oral capsule taken once daily for 52 weeks to establish optimal dose for weight loss over the course of the study.</description>
          </group>
          <group group_id="O3">
            <title>Naltrexone 50mg</title>
            <description>Oral Naltrexone 50mg capsule taken once daily for 52 weeks
Naltrexone: 25 or 50mg (randomized) oral capsule taken once daily for 52 weeks to establish optimal dose for weight loss over the course of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Glycosylated Hemoglobin (HbA1c) From Baseline</title>
          <description>Glycosylated hemoglobin (HbA1c) will be collected over the course of participation and changes will be evaluated at study endpoint.</description>
          <population>Analysis population consists of participants who were randomized, received at least 1 dose of the trial compound (naltrexone or placebo), and had at least 1 assessment after baseline.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.007" spread="0.11"/>
                    <measurement group_id="O2" value="-0.061" spread="0.15"/>
                    <measurement group_id="O3" value="0.060" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.96</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Estimated treatment differences between groups analyzed using mixed-model analysis. Model includes the baseline value age; sex; compliance; ethnicity.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Insulin From Baseline</title>
        <description>Insulin will be collected over the course of participation and changes will be evaluated at study endpoint.</description>
        <time_frame>Week 52</time_frame>
        <population>Analysis population consists of participants who were randomized, received at least 1 dose of the trial compound (naltrexone or placebo), and had at least 1 assessment after baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral placebo capsule taken once daily for 52 weeks
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone 25mg</title>
            <description>Oral Naltrexone 25mg capsule taken once daily for 52 weeks
Naltrexone: 25 or 50mg (randomized) oral capsule taken once daily for 52 weeks to establish optimal dose for weight loss over the course of the study.</description>
          </group>
          <group group_id="O3">
            <title>Naltrexone 50mg</title>
            <description>Oral Naltrexone 50mg capsule taken once daily for 52 weeks
Naltrexone: 25 or 50mg (randomized) oral capsule taken once daily for 52 weeks to establish optimal dose for weight loss over the course of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Insulin From Baseline</title>
          <description>Insulin will be collected over the course of participation and changes will be evaluated at study endpoint.</description>
          <population>Analysis population consists of participants who were randomized, received at least 1 dose of the trial compound (naltrexone or placebo), and had at least 1 assessment after baseline.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.45" spread="4.89"/>
                    <measurement group_id="O2" value="0.45" spread="6.23"/>
                    <measurement group_id="O3" value="2.16" spread="5.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.92</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Estimated treatment differences between groups analyzed using mixed-model analysis. Model includes the baseline value age; sex; compliance; ethnicity.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Total Cholesterol From Baseline</title>
        <description>Total Cholesterol will be collected over the course of participation and changes will be evaluated at study endpoint.</description>
        <time_frame>Week 52</time_frame>
        <population>Analysis population consists of participants who were randomized, received at least 1 dose of the trial compound (naltrexone or placebo), and had at least 1 assessment after baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral placebo capsule taken once daily for 52 weeks
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone 25mg</title>
            <description>Oral Naltrexone 25mg capsule taken once daily for 52 weeks
Naltrexone: 25 or 50mg (randomized) oral capsule taken once daily for 52 weeks to establish optimal dose for weight loss over the course of the study.</description>
          </group>
          <group group_id="O3">
            <title>Naltrexone 50mg</title>
            <description>Oral Naltrexone 50mg capsule taken once daily for 52 weeks
Naltrexone: 25 or 50mg (randomized) oral capsule taken once daily for 52 weeks to establish optimal dose for weight loss over the course of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Total Cholesterol From Baseline</title>
          <description>Total Cholesterol will be collected over the course of participation and changes will be evaluated at study endpoint.</description>
          <population>Analysis population consists of participants who were randomized, received at least 1 dose of the trial compound (naltrexone or placebo), and had at least 1 assessment after baseline.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.16" spread="5.12"/>
                    <measurement group_id="O2" value="1.52" spread="6.41"/>
                    <measurement group_id="O3" value="-3.02" spread="5.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.98</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Estimated treatment differences between groups analyzed using mixed-model analysis. Model includes the baseline value age; sex; compliance; ethnicity.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in HDL From Baseline</title>
        <description>High-density lipoprotein (HDL) will be collected over the course of participation and changes will be evaluated at study endpoint.</description>
        <time_frame>Week 52</time_frame>
        <population>Analysis population consists of participants who were randomized, received at least 1 dose of the trial compound (naltrexone or placebo), and had at least 1 assessment after baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral placebo capsule taken once daily for 52 weeks
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone 25mg</title>
            <description>Oral Naltrexone 25mg capsule taken once daily for 52 weeks
Naltrexone: 25 or 50mg (randomized) oral capsule taken once daily for 52 weeks to establish optimal dose for weight loss over the course of the study.</description>
          </group>
          <group group_id="O3">
            <title>Naltrexone 50mg</title>
            <description>Oral Naltrexone 50mg capsule taken once daily for 52 weeks
Naltrexone: 25 or 50mg (randomized) oral capsule taken once daily for 52 weeks to establish optimal dose for weight loss over the course of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in HDL From Baseline</title>
          <description>High-density lipoprotein (HDL) will be collected over the course of participation and changes will be evaluated at study endpoint.</description>
          <population>Analysis population consists of participants who were randomized, received at least 1 dose of the trial compound (naltrexone or placebo), and had at least 1 assessment after baseline.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="1.73"/>
                    <measurement group_id="O2" value="0.79" spread="2.19"/>
                    <measurement group_id="O3" value="0.36" spread="1.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.95</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Estimated treatment differences between groups analyzed using mixed-model analysis. Model includes the baseline value age; sex; compliance; ethnicity.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in LDL From Baseline</title>
        <description>Low-density lipoprotein (HDL) will be collected over the course of participation and changes will be evaluated at study endpoint.</description>
        <time_frame>Week 52</time_frame>
        <population>Analysis population consists of participants who were randomized, received at least 1 dose of the trial compound (naltrexone or placebo), and had at least 1 assessment after baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral placebo capsule taken once daily for 52 weeks
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone 25mg</title>
            <description>Oral Naltrexone 25mg capsule taken once daily for 52 weeks
Naltrexone: 25 or 50mg (randomized) oral capsule taken once daily for 52 weeks to establish optimal dose for weight loss over the course of the study.</description>
          </group>
          <group group_id="O3">
            <title>Naltrexone 50mg</title>
            <description>Oral Naltrexone 50mg capsule taken once daily for 52 weeks
Naltrexone: 25 or 50mg (randomized) oral capsule taken once daily for 52 weeks to establish optimal dose for weight loss over the course of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in LDL From Baseline</title>
          <description>Low-density lipoprotein (HDL) will be collected over the course of participation and changes will be evaluated at study endpoint.</description>
          <population>Analysis population consists of participants who were randomized, received at least 1 dose of the trial compound (naltrexone or placebo), and had at least 1 assessment after baseline.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.87" spread="4.47"/>
                    <measurement group_id="O2" value="1.14" spread="5.46"/>
                    <measurement group_id="O3" value="-4.40" spread="4.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.43</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Estimated treatment differences between groups analyzed using mixed-model analysis. Model includes the baseline value age; sex; compliance; ethnicity.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 52 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Oral placebo capsule taken once daily for 52 weeks
Placebo</description>
        </group>
        <group group_id="E2">
          <title>Naltrexone 25mg</title>
          <description>Oral Naltrexone 25mg capsule taken once daily for 52 weeks
Naltrexone: 25 or 50mg (randomized) oral capsule taken once daily for 52 weeks to establish optimal dose for weight loss over the course of the study.</description>
        </group>
        <group group_id="E3">
          <title>Naltrexone 50mg</title>
          <description>Oral Naltrexone 50mg capsule taken once daily for 52 weeks
Naltrexone: 25 or 50mg (randomized) oral capsule taken once daily for 52 weeks to establish optimal dose for weight loss over the course of the study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cocaine Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Reduced salivation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Stomach pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia/Fatigability</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Tension/Inner unrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Concentration difficulties</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Sleepiness/Sedation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Increased sleep</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Reduced sleep</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Diminished sexual desire</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Associate Professor of Psychiatry; Director, Psychosis Program, CMHC</name_or_title>
      <organization>Connecticut Mental Health Center</organization>
      <phone>(203) 974-7500</phone>
      <email>cenk.tek@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

